Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.66 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605608 | 0.99 | PTGS2 (0.65) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL5605936 | 0.97 | PTGS2 (0.66) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| Hydrochloric Acid SCHEMBL7105345 | 0.88 | PTGS2 (0.55) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL12884181 | 0.86 | PTGS2 (0.64) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL5494779 | 0.83 | PTGS2 (0.50) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL13291869 | 0.82 | PTGS2 (0.60) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL9523336 | 0.81 | PTGS2 (0.59) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL3105481 | 0.81 | PTGS2 (0.59) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL11446179 | 0.81 | PTGS2 (0.59) | PTGS2FAAHPTGS1CXCR1CXCR2 | |
| SCHEMBL2129263 | 0.81 | PTGS2 (0.59) | PTGS2FAAHPTGS1CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | PTGS2 653/4885FAAH 2065/4885PTGS1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.